Investors
People are different and so is their cancer, patients should be treated individually.
New The power of precision, For Every Oncologist, Today
With IndiTreat, 2cureX makes the testing of chemotherapeutic agents on patient-derived microtumors an operational reality.
Read
Latest News
The latest news around the IndiTreat® clinical trial in colorectal cancer patients that met its primary endpoint.
Read more
Please click here to download our Articles of association
Redeye Investor theme: Medtech & Diagnostics, Stockholm
Life Science Investor Conference, Copenhagen
Interim Report Q1 2021
View previous reports
Annual General Meeting
IndiTreat® supports genomic characterization of tumors with unique functional information of treatment resistance and sensitivity.
